The U.S. Food and Drug Administration says its ongoing safety review of the nation’s main abortion pill will continue into next year. Both outlets report that the agency has not yet concluded the review and expects the process to extend beyond the current year.
The coverage is limited, but the central point is consistent: the FDA is continuing its assessment rather than issuing a final determination immediately. The reports frame the extension as part of the FDA’s standard review timeline for safety-related decisions, while also highlighting that the outcome remains pending. As a result, the pill’s regulatory status and any future changes depend on when the FDA completes its evaluation.
